Mrs. B, a 49-year-old woman, was diagnosed with invasive ductal carcinoma in her left breast in December 2000. She underwent various treatments including surgery, chemotherapy, radiotherapy, and targeted therapies like Herceptin. Despite complications and ongoing pain, she has shown resilience throu

1 views • 32 slides

An audit was conducted to monitor reactions to subcutaneous Herceptin administration, with a total of 618 doses given to 110 patients. Only 2.7% of patients experienced reactions. Recommendations on observation requirements post-administration were made based on the findings.

0 views • 12 slides